NCT05069935 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05069935
Title	FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Recruitment	Terminated
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Fate Therapeutics
Indications	head and neck squamous cell carcinoma triple-receptor negative breast cancer skin squamous cell carcinoma Her2-receptor positive breast cancer esophageal cancer Advanced Solid Tumor endometrial carcinoma renal cell carcinoma lung small cell carcinoma skin melanoma colorectal cancer cervical cancer lung non-small cell carcinoma stomach cancer
Therapies	Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine
Age Groups:	senior \| adult
Covered Countries	USA

Additional content available in CKB BOOST